医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives Japanese Patent for Spinal Disc Tissue Engineering

2013年07月11日 PM11:25
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the Japan Patent Office issued a Certificate Of Patent on its patent application “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor” to regrow the spinal disc, using human dermal fibroblasts. The allowed claims include the use of human dermal fibroblasts from the patient’s own body, to regrow the nucleus of the spinal disc in vivo.

The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.

“This is a major addition to our growing patent portfolio and further distinguishes SpinalCyte as the international leader for regeneration of the spinal disc,” said Pete O’Heeron, Chief Executive Officer. “This is our first Japanese Patent and we are excited the Japanese Patent Office has validated the uniqueness of our technology.”

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company founded in 2007 for the purpose of developing an innovative and autologous solution for nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a nucleus regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281-461-6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc